Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531351 | 0.94 | NOS1 (0.42) | CDANOS3NOS1ALDH1A1OPRM1 | |
| SCHEMBL25307809 | 0.90 | CDA (0.46) | CDANOS3NOS1ALDH1A1OPRM1 | |
| SCHEMBL6082054 | 0.90 | CDA (0.46) | CDANOS3NOS1ALDH1A1OPRM1 | |
| SCHEMBL10982543 | 0.90 | CDA (0.46) | CDANOS3NOS1ALDH1A1OPRM1 | |
| SCHEMBL19271812 | 0.89 | CDA (0.42) | CDANOS3NOS1ALDH1A1OPRM1 | |
| SCHEMBL11215508 | 0.88 | CDA (0.44) | CDANOS3NOS1ALDH1A1OPRM1 | |
| SCHEMBL9202125 | 0.87 | KDM4E (0.39) | ALDH1A1OPRM1OPRL1KMT2A | |
| SCHEMBL17138754 | 0.85 | CDA (0.42) | CDANOS3NOS1ALDH1A1MEN1 | |
| SCHEMBL3093245 | 0.85 | PDE7A (0.41) | ALDH1A1OPRM1OPRL1MAPTKMT2A | |
| SCHEMBL16400703 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0234331-A1 | Octahydropyrido[1,2-c]-pyrimidinones | G.D. Searle & Co. (US) | 1987-09-02 | — | — | EP | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0234331-A1 | Octahydropyrido[1,2-c]-pyrimidinones | G.D. Searle & Co. (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0234331-A1 | Octahydropyrido[1,2-c]-pyrimidinones | G.D. Searle & Co. (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4680295-A | ANTIARRHYTHMIA AGENTS | G. D. SEARLE & CO. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4680295-A | ANTIARRHYTHMIA AGENTS | G. D. SEARLE & CO. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4680295-A | ANTIARRHYTHMIA AGENTS | G. D. SEARLE & CO. (US) | 1987-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | CDA 3163/4885NOS3 1656/4885NOS1 2282/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | CDA 3693/4885NOS3 1650/4885NOS1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.